A pilot study of regenerative therapy using controlled release of recombinant human fibroblast growth factor for patients with pre-collapse osteonecrosis of the femoral head

被引：0
|
作者：
Yutaka Kuroda
Ryuta Asada
Kazutaka So
Atsushi Yonezawa
Manabu Nankaku
Kumi Mukai
Toshiko Ito-Ihara
Harue Tada
Michio Yamamoto
Toshinori Murayama
Satoshi Morita
Yasuhiko Tabata
Masayuki Yokode
Akira Shimizu
Shuichi Matsuda
Haruhiko Akiyama
机构：
[1] Kyoto University,Department of Orthopaedic Surgery, Graduate School of Medicine
[2] Gifu University Hospital,Clinical Research Center
[3] Kyoto University Hospital,Department of Clinical Pharmacology and Therapeutics
[4] Kyoto University Hospital,Rehabilitation Unit
[5] Kyoto University Hospital,Department of Clinical Innovative Medicine, Institute for Advancement of Clinical and Translational Research (iACT)
[6] Kyoto University Hospital,Department of Data Science, Institute for Advancement of Clinical and Translational Research (iACT)
[7] Kyoto University Hospital,Department of Experimental Therapeutics, Institute for Advancement of Clinical and Translational Research (iACT)
[8] Kyoto University,Department of Biomaterials, Field of Tissue Engineering, Institute for Frontier Medical Sciences
[9] Gifu University,Department of Orthopaedic Surgery
来源：
International Orthopaedics | 2016年 / 40卷
关键词：
Clinical trial; Femoral head; FGF; Growth factor; Osteonecrosis; Regenerative therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1747 / 1754
页数：7
相关论文
共 50 条
  • [41] Epithelial pearl formation following tympanic membrane regeneration therapy using an atelocollagen/silicone membrane and basic fibroblast growth factor: Our experience from a retrospective study of one hundred sixteen patients
    Hakuba, N.
    Hato, N.
    Omotehara, Y.
    Okada, M.
    Gyo, K.
    CLINICAL OTOLARYNGOLOGY, 2013, 38 (05) : 394 - 397
  • [42] The therapeutic effect of recombinant human epidermal growth factor (rhEGF) on mucositis in patients with head and neck cancer undergoing radiotherapy with or without chemotherapy: A double-blind placebo-controlled prospective phase II multi-institutional clinical trial
    Lee, S.
    Wu, H.
    Song, S.
    Kim, Y.
    Oh, Y.
    Lee, C.
    Keum, K.
    Ahh, Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S32 - S32
  • [43] Therapeutic Effect of Recombinant Human Epidermal Growth Factor (RhEGF) on Mucositis in Patients Undergoing Radiotherapy, With or Without Chemotherapy, for Head And Neck Cancer A Double-blind Placebo-controlled Prospective Phase 2 Multi-institutional Clinical Trial
    Wu, Hong Gyun
    Song, Si Yeol
    Kim, Yeon Sil
    Oh, Young Taek
    Lee, Chang Geol
    Keum, Ki Chang
    Ahn, Yong Chan
    Lee, Sang-wook
    CANCER, 2009, 115 (16) : 3699 - 3708
  • [44] Pilot phase I study of gefitinib (GEF) in combination with paclitaxel (PAC) and radiation therapy (RT) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) and effects on epidermal growth factor receptor (EGFR) signaling pathway
    Morris, J. C.
    Allen, C.
    Citrin, D.
    Gius, D.
    Chen, Z.
    Colevas, A. D.
    Harold, N.
    Rudy, S.
    Singh, A. K.
    VanWaes, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [45] Rationale and design for the study of recombinant human hepatocyte growth factor plasmid in the treatment of patients with chronic limb-threatening ischemia (HOPE CLTI): Randomized, placebo-controlled, double-blind, III clinical trials
    Di, Xiao
    Liu, Changwei
    Ni, Leng
    Ye, Wei
    Rong, Zhihua
    Zhang, Rui
    Niu, Shuai
    Li, Fengshi
    Zheng, Yuehong
    Han, Chengquan
    Liu, Yue
    AMERICAN HEART JOURNAL, 2022, 254 : 88 - 101
  • [46] Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia—a randomized, placebo-controlled, double-blind safety and efficacy study
    K. Geissler
    J. A. Liu Yin
    A. Ganser
    M. A. Sanz
    J. Szer
    A. Raghavachar
    D. Hoelzer
    C. Martinez
    K. Taylor
    L. Kanz
    L. B. To
    E. Archimbaud
    Annals of Hematology, 2003, 82 : 677 - 683
  • [47] Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia - a randomized, placebo-controlled, double-blind safety and efficacy study
    Geissler, K
    Yin, JAL
    Ganser, A
    Sanz, MA
    Szer, J
    Raghavachar, A
    Hoelzer, D
    Martinez, C
    Taylor, K
    Kanz, L
    To, LB
    Archimbaud, E
    ANNALS OF HEMATOLOGY, 2003, 82 (11) : 677 - 683
  • [48] Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers - A phase III randomized placebo-controlled double-blind study
    Wieman, TJ
    Smiell, JM
    Su, YC
    DIABETES CARE, 1998, 21 (05) : 822 - 827
  • [49] Randomized, placebo-controlled study of recombinant human interleukin eleven (Neumega(TM) rhIL-11 growth factor) in patients with breast cancer following high-dose chemotherapy with autologous hematopoietic progenitor cell (AHPC) support.
    Hussein, A
    Vredenburgh, J
    Elkordy, M
    Rubin, P
    Fisher, D
    Canales, R
    Petros, W
    Gilbert, C
    Peret, N
    Dykstra, K
    Loewy, J
    Kaye, JA
    Peters, WP
    EXPERIMENTAL HEMATOLOGY, 1996, 24 (09) : 634 - 634
  • [50] Prior and concurrent administration of recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia-A randomized, placebo-controlled, double blind, safety and efficacy study.
    Geissler, K
    Yin, JAL
    Ganser, A
    Sanz, MA
    Szer, J
    Raghavachar, A
    Hoelzer, D
    Martinez, C
    Taylor, K
    Kanz, L
    To, LB
    Archimbaud, E
    BLOOD, 2001, 98 (11) : 799A - 799A
12345